Long-term human IgG treatment improves heart and muscle function in a mouse model of Duchenne muscular dystrophy

Type of publication: Academic publication
Disease: Duchenne muscular dystrophy

Authors:

Jana Zschüntzsch, Pia Vanessa Jouvenal, Yaxin Zhang, Florian Klinker, Malte Tiburcy, David Liebetanz, Dörthe Malzahn, Heinrich Brinkmeier & Jens Schmidt


Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by mutations in the dystrophin gene, which leads to structural instability of the dystrophin–glycoprotein-complex with subsequent muscle degeneration. In addition, muscle inflammation has been implicated in disease progression and therapeutically addressed with glucocorticosteroids. These have numerous adverse effects. Treatment with human immunoglobulin G (IgG) improved clinical and para-clinical parameters in the early disease phase in the well-established mdx mouse model. The aim of the present study was to confirm the efficacy of IgG in a long-term pre-clinical study in mdx mice.


Published: 25 February 2020
Journal: Journal of Cachexia, Sarcopenia and Muscle

Link: doi.org/10.1002/jcsm.12569

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern